PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 69.08

Change

+1.40 (+2.07)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+2.32 (+1.66%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+1.16 (+1.74%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+1.54 (+1.42%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.95 (+2.11%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.57 (+2.60%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.88 (+2.83%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+2.59 (+2.69%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+1.15 (+3.91%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.37 (+2.27%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.63 (+2.91%)

USD 8.55M

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.83% 62% D 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.83% 62% D 65% D
Trailing 12 Months  
Capital Gain 5.13% 52% F 46% F
Dividend Return 0.05% 13% F N/A F
Total Return 5.18% 52% F 34% F
Trailing 5 Years  
Capital Gain 21.47% 43% F 61% D-
Dividend Return 0.13% 11% F N/A F
Total Return 21.60% 43% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 5.56% 62% D 52% F
Dividend Return 5.57% 52% F 45% F
Total Return 0.01% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 20.78% 48% F 53% F
Risk Adjusted Return 26.82% 52% F 41% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.